EQS-News: Prof. Dr. Michael A. Rübhausen Joins the Medical Advisory Board of Viromed Medical AG
|
EQS-News: Viromed Medical AG
/ Key word(s): Miscellaneous
Prof. Dr. Michael A. Rübhausen Joins the Medical Advisory Board of Viromed Medical AG Rellingen, September 2, 2026 – Viromed Medical AG (“Viromed”; ISIN: DE000A40ZVN7), a medical technology company and pioneer in cold plasma technology, has appointed Prof. Dr. Michael A. Rübhausen to its Medical Advisory Board with immediate effect. The physicist and expert in spectroscopy strengthens the Advisory Board with his scientific expertise in the fields of spectroscopy and materials research. Uwe Perbandt, CEO of Viromed Medical AG: “With Prof. Dr. Michael A. Rübhausen, we are gaining a proven expert in modern spectroscopy and materials research for our Medical Advisory Board. His expertise is intended to help us thoroughly evaluate scientific questions at the intersection of material properties, spectroscopy, and cold plasma, and support our further research work.” Prof. Dr. Michael A. Rübhausen heads the Optics Working Group at the Institute of Nanostructure and Solid-State Physics at Universität Hamburg and also serves as the Institute’s Managing Director. He is affiliated with the Center for Free-Electron Laser Science (CFEL). His research focuses on modern spectroscopic methods – including Raman spectroscopy and ellipsometry – which he uses, among other things, to study superconductors, quantum materials, and biological and inorganic samples at the large-scale research facilities PETRA III and FLASH. His interdisciplinary scientific work encompasses more than 180 publications with approximately 4,000 citations, including contributions to renowned scientific journals such as Physical Review Letters, JACS, Angewandte Chemie, Nature Chemistry, Nature Physics, Cellular and Molecular Life Sciences, and Nature Communications. Another focus of his work is the methodological development of AI-supported analysis workflows for complex and high-dimensional datasets.
About Viromed Medical AG Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. Viromed can draw on a broad customer base in the DACH region and beyond. Viromed is pursuing the goal of further advancing the use of cold plasma technology in medicine in the coming years and realizing the corresponding growth potential. www.viromed-medical-ag.de
Contact Viromed E-Mail: kontakt@viromed-medical.de
Press contact E-Mail: viromed@kirchhoff.de
02.09.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | Viromed Medical AG |
| Hauptstraße 105 | |
| 25462 Rellingen | |
| Germany | |
| E-mail: | kontakt@viromed-medical.de |
| Internet: | https://www.viromed-medical-ag.de/ |
| ISIN: | DE000A40ZVN7 |
| WKN: | A40ZVN |
| Listed: | Regulated Unofficial Market in Dusseldorf, Frankfurt, Hamburg, Tradegate BSX |
| LEI Code: | 894500XR05MYCVCCR171 |
| EQS News ID: | 2392688 |
| End of News | EQS News Service |
|
|
2392688 02.09.2026 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | ||
| Sales1 | 0,00 | 0,00 | 0,00 | 0,00 | 1,13 | 5,09 | 8,50 | |
| EBITDA1,2 | 0,00 | 0,00 | 0,00 | -0,11 | 4,98 | 2,25 | 0,00 | |
| EBITDA-Margin3 | 0,00 | 0,00 | 0,00 | 0,00 | 442,93 | 44,25 | 0,00 | |
| EBIT1,4 | 0,00 | 0,00 | 0,00 | -0,11 | 4,73 | 1,73 | 8,00 | |
| EBIT-Margin5 | 0,00 | 0,00 | 0,00 | 0,00 | 420,44 | 33,95 | 94,12 | |
| Net Profit (Loss)1 | 0,00 | 0,00 | 0,00 | -0,11 | -3,09 | 0,60 | 0,00 | |
| Net-Margin6 | 0,00 | 0,00 | 0,00 | 0,00 | -274,84 | 11,87 | 0,00 | |
| Cashflow1,7 | 0,00 | 0,00 | 0,00 | -0,11 | -2,84 | 1,13 | 0,00 | |
| Earnings per share8 | 0,00 | 1,23 | -0,01 | -0,01 | -0,15 | 0,03 | 0,06 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Bernd Lenzen
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Viromed Medical | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A40ZVN | DE000A40ZVN7 | AG | 121,13 Mio € | 04.05.2022 | 9F5FMR3F+R3 | |
| PE 2027e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 57,00 | 0,00 | 0,00 | 285,00 | 11,56 | 107,38 | 23,81 |
|
Dividend '2024 in € |
Dividend '2025 in € |
Dividend '2026e in € |
Div.-Yield '2026e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 06.07.2026 | 30.09.2026 | 22.05.2026 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -19,56% | -6,91% | +44,74% | +74,05% | +14,58% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
